Prices are checked against each store and labelled with when.
It checks today's price at every store, compares the alternatives and answers in about a minute.
Mounjaro KwikPen is Eli Lilly's once-weekly injectable pen containing tirzepatide, a single molecule that acts on both GIP and GLP-1 receptors. It is a prescription medicine for adults with type 2 diabetes, used alongside diet and exercise to improve blood sugar. The pen comes in six strengths from 2.5 mg to 15 mg per 0.5 mL, which lets a clinician step the dose up gradually. Compared with single-receptor GLP-1 drugs, its dual action is the main distinction; it is not for type 1 diabetes, and its safety under 18 and in people with pancreatitis is not established.
In stockReturn policy
Mounjaro KwikPen is an injection pen from Eli Lilly. It contains tirzepatide and is given once a week as an injection under the skin. Tirzepatide is a single molecule designed to bind to both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors.
Mounjaro is a prescription medicine for adults with type 2 diabetes. It is used along with diet and exercise to improve blood sugar levels. It is not for people with type 1 diabetes. It is not known whether it is suitable for people with pancreatitis, or whether it is safe and effective for children under 18.